Delivery Order SPE2DR25D2001-SPE2DR26FBFS7
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of Gemtesa 75 mg tablets (90-count units) with a ceiling value of $4,606.47. This delivery order represents a firm fixed-price, non-set-aside contract to be completed by September 15, 2025, and will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The award is issued under the company's existing Indefinite Delivery Contract with DLA...
- The Defense Logistics Agency awarded a delivery order valued at $7,531.09 to AmerisourceBergen Drug Corp for the supply of Gemtesa 75 mg tablets (30-count units) on September 4, 2025, with completion expected by September 5, 2025. This non-set-aside contract utilizes firm fixed pricing and represents a delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 vehicle running through December 2026. The order will be...
- The Defense Logistics Agency awarded a $7,448.66 delivery order to AmerisourceBergen Drug Corp on April 22, 2025, for the supply of Gemtesa 75 mg tablets (90 count). This is a firm fixed price, non-set-aside contract with a completion date of April 23, 2025, and performance to be executed in Conshohocken, Pennsylvania. The award represents a child delivery order issued under AmerisourceBergen's larger pharmaceutical supply agreement with the DLA. This delivery order falls under...
- The Defense Logistics Agency awarded a $1,078.72 delivery order to AmerisourceBergen Drug Corp on November 25, 2025, for the supply of Gemtesa 75 mg tablets (90-count package). This firm fixed-price, competitively awarded contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (contract SPE2DX), valued at $999,999,999.00 and extending through December 2026. The place of performance is AmerisourceBergen's corporate...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order on December 1, 2025, for Gemtesa 75 mg tablets (90-count), valued at $6,002.46 under a firm fixed-price contract type with no set-aside designation. The order is due for completion by December 2, 2025, and will be fulfilled from the contractor's Conshohocken, Pennsylvania location. This delivery order is a child contract issued under AmerisourceBergen's substantial Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency awarded a delivery order valued at $3,869.18 to AmerisourceBergen Drug Corp for Gemtesa 75 mg tablets (30-count supply) on August 8, 2025, with an ultimate completion date of August 11, 2025. This firm fixed-price, competitively awarded contract involves no set-aside designation and specifies Conshohocken, Pennsylvania as the place of performance. The award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 25, 2025, for the supply of Gemtesa 75 mg tablets (90-count units) valued at $8,353.48. This firm fixed-price delivery order, with an ultimate completion date of November 26, 2025, represents a non-set-aside, competitively awarded contract. The pharmaceutical product will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a $10,456.11 firm fixed-price delivery order to AmerisourceBergen Drug Corp on July 14, 2025, for the supply of Gemtesa 75 mg tablets (90-count units). The contract, which represents a non-competitive delivery order, is scheduled for completion by July 15, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This award is a child delivery order executed under AmerisourceBergen Drug Corp's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $13,881.40 to AmerisourceBergen Drug Corp for the supply of Gemtesa 75 mg tablets (90 count) on July 25, 2025, with an ultimate completion date of July 28, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of Gemtesa 75 mg tablets (90-count units) under a firm fixed price contract valued at $43,743.38. This is a non-set-aside, competitively awarded delivery order with an ultimate completion date of September 17, 2025. The contract is performed from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary operations as...
- SPE2DR25D2001Indefinite Delivery Contract
- SPE2DR25D2001-SPE2DR26FBFS7Delivery Order
The Defense Logistics Agency awarded a $27,132.48 delivery order to AmerisourceBergen Drug Corp on December 2, 2025, for the supply of Gemtesa 75 mg tablets (90-count packages). This firm fixed-price, non-set-aside contract is scheduled for completion by December 3, 2025, and will be fulfilled from the vendor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's broader indefinite delivery contract with DLA Troop Support Medical. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical vendor for federal military and veteran healthcare procurement through its $999,999,999.00 indefinite delivery contract with DLA Troop Support Medical (SPE2DX), which extends through December 2026. This prime contract vehicle enables the company to supply a comprehensive range of pharmaceutical products, medical devices, and specialized healthcare commodities to support Defense Health Agency and other federal healthcare systems globally. The current delivery order for Gemtesa, a pharmaceutical treatment, exemplifies the company's role in fulfilling ongoing federal medical supply requirements through competitively awarded contracts with firm fixed pricing structures.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $27.1k | 12/1/25 |